Pharmaceutical Commercialisation & Funding week2

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/30

encourage image

There's no tags or description

Looks like no tags are added yet.

31 Terms

1
New cards

Commercialisation

Taking a pharmaceutical idea/technology and developing it into a product that can be marketed and sold

2
New cards

NCE meaning

New Chemical Entities = new molecules that can be used as medicines

3
New cards

Non-NCE

Exisitng drugs that are improved or reformulated

4
New cards

Enabling technologies

Technologies that help medicines work better

5
New cards

NCE pathway

  • undegoes development pathway

  • discovery

  • preclinical testing

  • Phase 1-3

  • Regulatory Review

  • Approval

  • Commercial product

  • post-market surveillance


6
New cards

Cons of NCE

  • very expensive: 1-2 mil

  • very slow: more than 10 yrs

  • high risk: many products fail during development


7
New cards

505 (b) 1

New drug/NCE

8
New cards

ANDA

Generic drugs

9
New cards

OTC monograph

certain over-the-counter drugs

10
New cards

505 (b)2

modified exisiting drugs

  • an abbreviated approval pathway

  • applicant can rely partly on existing information/data that they did not generate themselves


11
New cards

Examples of 505 (b) 2

  • dosage form

  • strength dose

  • route of administration

  • API in a combination product

  • modify an exisitng drug + use existing data = potentially faster


12
New cards

Super generics

Existing drug + innovative formulation

  • faster

  • cheaper

  • improved

  • lower risk


13
New cards

improve PK

  • increase absorption

  • increase bioavailabity

  • faster action

  • lower dose


14
New cards

improve PD

  • change distribution

  • increase efficacy

  • decrease toxicity


15
New cards

Development stages

  1. Research: make the molecule/technology

  2. Prove: proof of concept

  3. protect: IP

  4. improve: prototype optimisation

  5. test: preclinical + clinical

  6. approve: regulatory approval

  7. sell: marketing/commercialisation


16
New cards

6 funding types Give A Very Important Little Drug

  1. Grant funding: by government/research bodies (ARC/NHMRC)

  2. Angel investors

  3. Venture Captial

  4. Public equity/IPO

  5. Licensing or sale of technologu

  6. Debt finance


17
New cards

NHMRC

supports health and medical research

  • focus on health outcomes


18
New cards

Cons of Grant funding

  • depends on milestones

  • need strict reporting requirements

  • budget restrict

  • some schemes may require payback if commercialisation arrangement change


19
New cards

Angel investors

money invested into a private company by wealthy independent investors

  • provide money and sometimes experience/knowledge


20
New cards

What stage angel normally supports

from early stage

21
New cards

Venture capital (VC)

high-risk investment in businesses with a potential for rapid growth/high-returns

  • VC investors recieve shares/equity in exchange for investment


22
New cards

IPO

Initial public offering

  • lists on a stock exchange for the first time


23
New cards

where companies offer their shares

ASX = Australian Securities Exchange

24
New cards

Pros of IPO

  • can raise significant capital

  • access to public investors


25
New cards

Cons of IPO

  • intensive reporting

  • public scrutiny

  • must answer to shareholders

  • growth expectations

  • listing fees


26
New cards

Licensing

a company gives another party the right to use its technology

  • may recieve on return:

  • upfront payment

  • royalties


27
New cards

Why license technology?

  • original company may not have enough

  • money, skills, manufacturing capability, clinical trial resources


28
New cards

Major disadvantage of licensing

loss of control

29
New cards

Debt finance

borrow money from a bank/financial instituation

  • needs collateral

  • ability to repay the loan

  • higher risk due to higher interest rate


30
New cards

Accelerating Commercialisation

Can provide funding to assist eligible commercialisation costs.

31
New cards

R&D tax incentive

allows eligible companies to recieve a tax benefit/deduction for research activities